P Garrido1, A A Adjei2, J Bajpai3, S Banerjee4, A S Berghoff5, S P Choo6, E Felip7, A J S Furness8, E Garralda9, J Haanen10, A Letsch11, H Linardou12, S Peters13, C Sessa14, J Tabernero15, J Tsang16, J C-H Yang17, M C Garassino18. 1. Universidad de Alcalá, Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain. Electronic address: pilargarrido@gmail.com. 2. Mayo Clinic, Rochester, USA. 3. Tata Memorial Centre, Mumbai, India. 4. The Royal Marsden NHS Foundation Trust, Institute of Cancer Research, London, UK. 5. Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria. 6. Curie Oncology Singapore, National Cancer Centre Singapore, Singapore. 7. Medical Oncology Department, Vall d'Hebron University Hospital, Thoracic Oncology and H&N Cancer Unit, Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, Barcelona, Spain. 8. Royal Marsden NHS Foundation Trust, London, UK. 9. Early Drug Development Unit, VHIO - Vall d'Hebron Institute of Oncology, HUVH - Vall d'Hebron University Hospital, Barcelona, Spain. 10. Division of Medical Oncology, The Netherlands Cancer Institute (NKI), Amsterdam, Netherlands. 11. Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany. 12. 4th Oncology Department, Metropolitan Hospital, Athens, Greece. 13. Oncology Department - CHUV, Lausanne University, Lausanne. 14. Ente Ospedaliero Cantonale, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. 15. Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, Barcelona, Spain. 16. Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong. 17. Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. 18. Thoracic Oncology Unit, Medical Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Abstract
BACKGROUND: European Society for Medical Oncology Women for Oncology (ESMO W4O) research has previously shown under-representation of female oncologists in leadership roles. As early reports suggested disproportionate effects of the COVID-19 pandemic on women, the ESMO W4O Committee initiated a study on the impact of the pandemic on the lives of female and male oncologists. METHODS: A questionnaire was sent to ESMO members and put on the ESMO website between 8 June 2020 and 2 July 2020. Questions focused on the working (hospital tasks, laboratory tasks, science) and home (household management, childcare, parent care, personal care) lives of oncologists during and after COVID-19-related lockdowns. RESULTS: Of 649 respondents, 541 completed the questionnaire. Of these, 58% reported that COVID-19 had affected their professional career, 83% of whom said this was in a negative way (85% of women versus 76% of men). Approximately 86% reported that COVID-19 had changed their personal life and 82% their family life. Women were again significantly more affected than men: personal life (89% versus 78%; P = 0.001); family life (84% versus 77%; P = 0.037). During lockdowns, women reported increased time spent on hospital and laboratory tasks compared with men (53% versus 46% and 33% versus 26%, respectively) and a significantly higher proportion of women than men spent less time on science (39% versus 25%) and personal care (58% versus 39%). After confinement, this trend remained for science (42% versus 23%) and personal care (55% versus 36%). CONCLUSIONS: The COVID-19 pandemic has adversely affected the professional and home lives of oncologists, especially women. Reduced research time for female oncologists may have long-lasting career consequences, especially for those at key stages in their career. The gender gap for promotion to leadership positions may widen further as a result of the pandemic.
BACKGROUND: European Society for Medical Oncology Women for Oncology (ESMO W4O) research has previously shown under-representation of female oncologists in leadership roles. As early reports suggested disproportionate effects of the COVID-19 pandemic on women, the ESMO W4O Committee initiated a study on the impact of the pandemic on the lives of female and male oncologists. METHODS: A questionnaire was sent to ESMO members and put on the ESMO website between 8 June 2020 and 2 July 2020. Questions focused on the working (hospital tasks, laboratory tasks, science) and home (household management, childcare, parent care, personal care) lives of oncologists during and after COVID-19-related lockdowns. RESULTS: Of 649 respondents, 541 completed the questionnaire. Of these, 58% reported that COVID-19 had affected their professional career, 83% of whom said this was in a negative way (85% of women versus 76% of men). Approximately 86% reported that COVID-19 had changed their personal life and 82% their family life. Women were again significantly more affected than men: personal life (89% versus 78%; P = 0.001); family life (84% versus 77%; P = 0.037). During lockdowns, women reported increased time spent on hospital and laboratory tasks compared with men (53% versus 46% and 33% versus 26%, respectively) and a significantly higher proportion of women than men spent less time on science (39% versus 25%) and personal care (58% versus 39%). After confinement, this trend remained for science (42% versus 23%) and personal care (55% versus 36%). CONCLUSIONS: The COVID-19 pandemic has adversely affected the professional and home lives of oncologists, especially women. Reduced research time for female oncologists may have long-lasting career consequences, especially for those at key stages in their career. The gender gap for promotion to leadership positions may widen further as a result of the pandemic.
Authors: Cristian-Virgil Lungulescu; Adina Turcu-Stiolica; Cristina Lungulescu; Elena-Adriana Dumitrescu; Razvan-Aurelian Turcu-Stiolica; Vlad-Mihai Croitoru; Irina-Mihaela Cazacu; Adelina-Silvana Gheorghe; Dana-Lucia Stanculeanu; Daniel Sur Journal: Int J Environ Res Public Health Date: 2022-05-01 Impact factor: 4.614
Authors: K H J Lim; K Murali; E Thorne; K Punie; K Kamposioras; C Oing; M O'Connor; E Élez; T Amaral; P Garrido; M Lambertini; B Devnani; C B Westphalen; G Morgan; J B A G Haanen; C Hardy; S Banerjee Journal: ESMO Open Date: 2021-12-17
Authors: Paolo A Ascierto; Sanjiv S Agarwala; Christian Blank; Corrado Caracò; Richard D Carvajal; Marc S Ernstoff; Soldano Ferrone; Bernard A Fox; Thomas F Gajewski; Claus Garbe; Jean-Jacques Grob; Omid Hamid; Michelle Krogsgaard; Roger S Lo; Amanda W Lund; Gabriele Madonna; Olivier Michielin; Bart Neyns; Iman Osman; Solange Peters; Poulikos I Poulikakos; Sergio A Quezada; Bradley Reinfeld; Laurence Zitvogel; Igor Puzanov; Magdalena Thurin Journal: J Transl Med Date: 2022-09-04 Impact factor: 8.440